Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?

Ruben Mesa, Claire Harrison

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e508-e509
JournalThe Lancet Haematology
Volume4
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Drug and Narcotic Control

ASJC Scopus subject areas

  • Hematology

Cite this

Authors' reply to comment What should be the endpoints of a symptomatic drug and its control? / Mesa, Ruben; Harrison, Claire.

In: The Lancet Haematology, Vol. 4, No. 11, 01.11.2017, p. e508-e509.

Research output: Contribution to journalLetter

Mesa, Ruben ; Harrison, Claire. / Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?. In: The Lancet Haematology. 2017 ; Vol. 4, No. 11. pp. e508-e509.
@article{4299db3192d54943a1f411c4808ab895,
title = "Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?",
author = "Ruben Mesa and Claire Harrison",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/S2352-3026(17)30195-3",
language = "English (US)",
volume = "4",
pages = "e508--e509",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?

AU - Mesa, Ruben

AU - Harrison, Claire

PY - 2017/11/1

Y1 - 2017/11/1

UR - http://www.scopus.com/inward/record.url?scp=85042148224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042148224&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(17)30195-3

DO - 10.1016/S2352-3026(17)30195-3

M3 - Letter

VL - 4

SP - e508-e509

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 11

ER -